$4.86
0.31%
Nasdaq, Apr 21, 08:45 pm CET
ISIN
US00289Y1073
Symbol
ABEO
Sector
Industry

Abeona Therapeutics, Inc. Stock price

$4.84
-0.46 8.68% 1M
-1.90 28.19% 6M
-0.73 13.11% YTD
-3.09 38.97% 1Y
-1.86 27.73% 3Y
-53.41 91.69% 5Y
-78.66 94.20% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
-0.01 0.21%
ISIN
US00289Y1073
Symbol
ABEO
Sector
Industry

Key metrics

Market capitalization $236.19m
Enterprise Value $161.18m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 5.02
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-64.21m
Free Cash Flow (TTM) Free Cash Flow $-58.46m
Cash position $98.06m
EPS (TTM) EPS $-2.25
P/E forward negative
P/S forward 6.09
EV/Sales forward 4.16
Short interest 4.78%
Show more

Is Abeona Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Abeona Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Abeona Therapeutics, Inc. forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Abeona Therapeutics, Inc. forecast:

Buy
100%

Financial data from Abeona Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 3.89 3.89
22% 22%
-
-3.89 -3.89
1,397% 1,397%
-
- Selling and Administrative Expenses 22 22
55% 55%
-
- Research and Development Expense 34 34
11% 11%
-
-60 -60
34% 34%
-
- Depreciation and Amortization 3.89 3.89
22% 22%
-
EBIT (Operating Income) EBIT -64 -64
33% 33%
-
Net Profit -64 -64
18% 18%
-

In millions USD.

Don't miss a Thing! We will send you all news about Abeona Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Abeona Therapeutics, Inc. Stock News

Positive
Seeking Alpha
about 5 hours ago
Abeona's pz-cel gene therapy shows the most durable wound healing in RDEB patients with no treatment related severe adverse events. There have been no instances of Squamous Cell Carcinoma. The FDA's previous Complete Response Letter focused on manufacturing and control issues. Since those questions have been answered thoroughly, an approval is likely by April 29th. Pz-cel offers a durable, one-...
Positive
Seeking Alpha
9 days ago
Abeona Therapeutics is poised for significant growth in 2025, with potential FDA approvals for Pz-cel and UX111, driving our Buy rating. Pz-cel, targeting RDEB, shows promising clinical data and commercial prospects, with an expected FDA decision by April 29, 2025. UX111, aimed at MPS IIIA, also holds strong potential, with an FDA decision anticipated by August 18, 2025, and substantial market ...
Neutral
GlobeNewsWire
20 days ago
CLEVELAND, April 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
More Abeona Therapeutics, Inc. News

Company Profile

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.

Head office United States
CEO Vishwas Seshadri
Employees 136
Founded 1974
Website www.abeonatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today